A combination of a “targeted” therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer. Up to one-third of women with advanced, HER-2-positive breast cancer may develop metastases to the brain.